TriSalus Life Sciences Inc, popularly known as TLSI, is a pioneering medical and pharmaceutical company focused on the development and commercialization of groundbreaking technologies to manage solid tumors’ drug delivery. Its mission lies centrally in the advancement of effective treatment methodologies for patients suffering from hard-to-treat cancers like pancreatic, liver, and other solid tumor cancers.
As a healthcare company that stands at the forefront of innovation, TLSI digs into the power of its proprietary FDA-EUA-cleared technology, namely Pressure Enabled Drug Delivery (PEDD™), with SmartValve® technology, which has shown promising results in overcoming the limitations that standard chemo-administration encounters. It is believed that this advanced technology helps increase the drug absorption by the tumors, maximizing the effectiveness of oncology treatments.
Another prominent aspect of TLSI is its dedication to research and clinical investigations. The company conducts comprehensive clinical studies in collaboration with leading healthcare professionals and institutions. These studies are aimed towards exploring the potentials of PEDD technology in several interventions, including both first-line and salvage therapies. Through extensive research & development and clinical collaborations, TriSalus Life Sciences is committed to providing advanced treatment alternatives and setting new standards in cancer care.
Based in Westminster, Colorado, the company has a dynamic and qualified team of healthcare professionals, engineers, and clinicians who share the company's passion for transforming the lives of patients through its innovative health solutions. Besides, TLSI also maintains an unwavering commitment to safety, compliance, and clinical excellence, ensuring that it delivers the most effective, reliable, and safe solutions for cancer patients worldwide.
TriSalus Life Sciences Inc. is much more than just a pharmaceutical company; it combines science and technology to improve patient lives and change the way we think about cancer treatments. As the epitome of breakthrough medical technology, TLSI holds a significant position in the innovative field of oncology. Through continuous innovation and commitment, the company aims to make a substantial difference in the global health care sector, especially in drastically improving the quality of life for those battling cancer. With its focus strongly pivot around “life,” TriSalus Life Sciences Inc. continues to fuel its journey towards a healthier future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
The FDA has granted 510(k) clearance to TriSalus Life Sciences for its TriNav Advance device, designed to enhance tumor penetration during liver embolization procedures. This catheter-based system extends the company's Pressure-Enabled Drug Delivery (PEDD) technology to smaller hepatic vessels, utilizing a SmartValve mechanism to improve drug and microsphere delivery to tumors while minimizing exposure to healthy tissue. Preclinical studies have supported the effectiveness of PEDD in increasing therapeutic concentration within tumors.
TriSalus Life Sciences (NASDAQ:TLSI) shares rose 15.6% in pre-market trading after receiving 510(k) clearance from the FDA for its TriNav Advance device. This new device is designed to enhance pressure-enabled drug delivery in liver embolization procedures, particularly for smaller, distal vessels. TriSalus plans a limited market release in the coming weeks and previously raised its full-year 2026 revenue guidance.
TriSalus Life Sciences outlined its commercial expansion, product pipeline, and clinical strategy at Canaccord Genuity’s Global Growth Conference, focusing on its pressure-enabled delivery technology for solid tumors. The company is actively expanding its sales force and increasing physician education to broaden product adoption. A key potential catalyst is the pending FDA clearance for TriNav ADVANCE, which could significantly expand market reach, and management projects strong gross margins and a path to cash-flow positivity with new CMS reimbursement codes.
Wall Street Zen has downgraded TriSalus Life Sciences (NASDAQ:TLSI) from "Hold" to "Sell," while the overall analyst consensus for the stock remains a "Hold" with an average price target of $7.50. Despite the downgrade, TriSalus shares opened at $5.27, following a 6.4% decline, and its recent quarterly results met earnings expectations and exceeded revenue estimates. The company, a clinical-stage biotechnology firm focusing on oncology therapies, has seen varied ratings from other analysts, including reaffirmed "Sell" and "Buy" ratings with adjusted price targets.